GlassScriptPhysician profile
Siji Samuel
NPI 1801567359
$2,676.97
in general payments reported to CMS, 2019-2025
20 companies · $563 in 2025
The $563 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.00 · 2022: $604 · 2023: $927 · 2024: $527 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,175.83 | 2022-2025 | Farxiga, Lokelma |
| Veloxis Pharmaceuticals, INC. | $462.85 | 2022-2025 | Envarsus |
| Alexion Pharmaceuticals, INC. | $157.93 | 2022-2025 | Ultomiris |
| Vifor Pharma, INC. | $141.00 | 2022-2023 | Veltassa |
| Nxstage Medical, INC. | $130.54 | 2022-2025 | Nxstage System One, Nxstage Cartridge Express, Nxstage Pureflow Solution |
| Travere Therapeutics, INC. | $106.44 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $91.48 | 2023-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $64.49 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $54.72 | 2023 | Jynarque |
| Opko Pharmaceuticals, LLC | $44.41 | 2024 | Rayaldee |
| Apellis Pharmaceuticals, INC. | $32.84 | 2025 | Empaveli |
| Amgen INC. | $32.53 | 2023 | Parsabiv |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.56 | 2025 | |
| Kyowa Kirin, INC. | $25.05 | 2025 | |
| Ardelyx, INC. | $24.68 | 2025 | Ibsrela |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.13 | 2021 | |
| Cormedix INC. | $23.98 | 2025 | Defencath |
| Genzyme Corporation | $21.44 | 2023 | |
| Glaxosmithkline, LLC. | $17.08 | 2024 | Jesduvroq |
| Ani Pharmaceuticals, INC. | $16.99 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siji Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.